Preparation of a phase 1 SAD/MAD trial of the IV administered antimicrobial peptide OMN6 targeting drug-resistant acinetobacter baumannii
Ended Project Grant Awarded Last action
- Award ID
- R34AI155324
- Recipient
-
Omnix Medical LTD UEI VN2HCFMKR454
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $492,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $328,000.00 Federal
- $164,000.00 Non-federal
- Place of performance
- Israel
Award details come from USAspending.gov.
Description
- Abstract
- Omnix medical is developing novel antimicrobial peptides by applying their proprietary stabilization technology to cecropins, a unique family of antimicrobial peptides (amps) from the innate immune systems of insects, which exert a potent effect on the bacterial membrane, compromising its integrity, causing cell lysis and rapid bacterial death. Multi-drug resistant (MDR) bacteria such as acinetobacter baumannii (AB), especially carbapenem- resistant AB (crab), present an increasing healthcare challenge. AB is designated number one on the who/CDC pathogen-priority list. Following a robust candidate selection process, the peptide OMN6 has presented the best antimicrobial activity against AB. OMN6 has progressed through preclinical studies, elucidating its mechanism of action, showing promising in vivo efficacy in a variety of infection models, and showing no adverse effects in in vivo toxicity studies. IND- enabling studies are being completed, in anticipation of an IND submission. OMN6 was designated a qualified infectious disease product (qidp) by the FDA in 2017. Following a successful IND submission, omnix is planning a phase 1A clinical trial examining safety in healthy volunteers, utilizing a single ascending dose (SAD), and a phase 1B clinical trial examining safety and effectiveness of OMN6 administered with imipenem VS placebo with imipenem in patients, utilizing a multiple ascending dose (MAD) study design. The study outline currently anticipates a total number of 146 HV and patients recruited from a single site. This application seeks to bridge the GAP between IND submission and initiation of FDA approved clinical trials. Omnix will contract with iqvia™ (formerly IMS health & quintiles), the human data science company™, as a contract research organization in order to conduct the phase i trial, and as such iqvia will also be performing the trial start-up tasks outlined in this proposal. These include establishment of a project management structure and organization between omnix and iqvia; preparation of study material such as the clinical protocol and informed consent forms; identification and contact establishment with clinical sites; and support of regulatory activities, including FDA and IRB submissions.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $164,000 | $0 | |
| Original award | $164,000 | $164,000 |
Quick answers
Who received award R34AI155324?
R34AI155324 was awarded to Omnix Medical LTD by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 13, 2021.
How much is award R34AI155324 worth?
$492,000 has been obligated on R34AI155324: $328,000 in federal funding and $164,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award